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Abstract
Background: It is well known that pulmonary alveolar proteinosis(PAP) is characterised by accumulation of
surfactant lipids and proteins within airspaces. However, few previous data describe the serum lipid levels
associated with PAP.
Materials and methods: We retrospectively reviewed 25 patients with idiopathic PAP(iPAP). The serum lipid levels
of patients with idiopathic PAP were compared with those of the healthy volunteers. In patients and healthy
subjects, the LDL-C/HDL-C ratios were 2.94 ± 1.21 and 1.60 ± 0.70, respectively (p < 0.001), HDL-C were 1.11 ± 0.27
and 1.71 ± 0.71 respectively (p < 0.001). The values of LDL-C correlated significantly with those of PaO2 and PA-aO2
(r = -0.685, p = 0.003, and r = 0.688, p = 0.003, respectively). The values of LDL-C/HDL-C ratios also correlated with
PaO2 levels and PA-aO2 levels (r = -0.698, p = 0.003, and r = 0.653, p = 0.006, respectively). 11 and 13 patients
experienced respectively a decline in TC and LDL-C levels following whole lung lavage(WLL), the median decline
was 0.71 mmol/L(p < 0.009) and 0.47 mmol/L(p < 0.003), respectively.
Conclusions: the serum lipid levels, especially the levels of LDL-C and LDL-C/HDL-C, may reflect the severity of the
disease in PAP patients, and predict the therapeutic effect of WLL.
Keywords: pulmonary alveolar proteinosis, high-density lipoprotein cholesterol lipid, low-density lipoprotein cho-
lesterol, whole lung lavage
Background
Pulmonary alveolar proteinosis(PAP) is a rare disease
characterized by the accumulation of lipoproteinaceous
material in the alveoli[1]. Clinically, Three forms of PAP
have been described: congenital, secondary, and idio-
pathic. More than 90% of patients are idiopathic PAP
(iPAP), is specifically associated with the presence of
granulocyte-macrophage colony stimulating factor(GM-
CSF) autoantibodies that are thought to mediate patho-
genesis by eliminating GM-CSF bioactivity, thereby this
loss of functional GM-CSF results in a filling of the
alveolar spaces of the lungs with the lipoproteinaceous
material called pulmonary surfactant[2,3].
Pulmonary surfactant is comprised of 90% lipid, 10%
protein, and less than 1% carbohydrate. Cholesterol is
the major neutral lipid (up to 90%) in pulmonary surfac-
tant. At least 80% of the cholesterol present in the lung
[4], and virtually all that in surfactant, is derived from
circulating lipoproteins, with very low-density lipopro-
tein believed to be the major vehicle of delivery to the
lung [5]. Therefore, impaired lipid metabolism may play
an important role in the development of iPAP.
It has been reported[6] that serum levels of triglyceride
were higher in patients with idiopathic PAP, while HDL-
C levels were lower in patients. Similarly, serum levels of
cholestenoic acid were also significantly increased in the
PAP patients[7]. Elevated serum cholesterol levels have
been confirmed in 19% of PAP patients[1].
Based on these findings, the clinical relevance of lipid
metabolism in iPAP deserves further study. The current
study investigated these relationships to determine
whether serum lipid levels would provide valuable clini-
cal information to assess and monitor disease progres-
sion. We measured serum lipid levels from iPAP
patients and investigated their relation to severity mar-
kers for iPAP including serum lactate dehydrogenase
(LDH), arterial blood gases. We also assessed variations
of these lipids before and after whole lung lavage(WLL).
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Patients
We retrospectively reviewed 25 patients with idiopathic
PAP that were diagnosed by cytological examination of
BAL fluid and pathological examination of the lung tis-
sues. The aetiologies associated with secondary PAP
were not found in these patients. Data for the iPAP
patients were collected from Nanjing Chest Hospital
(Bronchalveolar Lavage Center) between 2006 and 2011.
Patients were excluded from the study if they had a his-
tory of diabetes mellitus, chronic liver or kidney disease,
cancer, or use of corticosteroids or lipid-lowing drugs.
Control groups
Using a case-controlled study design, data from healthy
volunteers(HA) were obtained from persons who were
examined in the Nanjing Chest Hospital between April
2010 and May 2011. All healthy volunteers were free of
symptoms and not taking any medications. The study
protocol was approved by the Human Ethics Review
Committees of Nanjing Chest Hospital and all study
participants provided written informed consent.
Assays
Pulmonary function testing(YLS9-HI-101, Japan) includ-
ing spirometry, plethysmography, carbon monoxide lung
transfer factor (TLCO), and analyses of arterial blood
gases(BJ05-400, Germany) were performed in most of
patients. Blood samples for PaO2 and PaCO2 values were
analysed at room air. PAO2 (alveolar oxygen tension) is
calculated by the following equation. PAO2 = (baro-
metric pressure - 47) × FiO2 -PaCO2/R. R, an exchange
ratio, is assumed as 0.8 in this study. The alveolar arterial
PO2 difference (PA-aO2) is calculated by subtracting
PaO2 from PAO2. Laboratory examinations were per-
formed on blood samples obtained after an overnight
fasting. The levels of serum lipid levels (total cholesterol
(TC), triglyceride (TG), low-density lipoprotein choles-
terol (LDL-C), high-density lipoprotein cholesterol
(HDL-C)), apolipoprotein-A1 (Apo-A1) and apolipopro-
tein-B (Apo-B), Lipoprotein(a)), and lactate dehydrogen-
ase (LDH) were measured with commercial kits using an
automated chemistry analyzer (OI Analytical, American).
Criteria of WLL
Whole lung lavage, the current standard of care for
treating autoimmune PAP, is effective in physically
removing the accumulated surfactant and is effective in
most patients[8]. The criteria for therapeutic lung lavage
in this study were as follow[9]: (1) presence of persistent
or progressive respiratory failure; (2) absence of respira-
tory difficulty at rest, but presence of exercise desatura-
tion; (3) a significant limitation in daily or sport
activities. Patients were examined with lipid levels and
arterial blood gas analysis after one week of WLL.
Statistical analysis
Statistics were performed with SPSS version 11.0. Paired
data comparisons were performed using a Wilcoxon
signed rank test. The nonparametric Mann-Whitney U-
test was used when data were not normally distributed.
The correlations between variables were determined by
Spearman rank correlation coefficients. P values of less
than 0.05 were considered statistically significant.
Results
I ti si n d i c a t e dt h a tt h em e d i a na g ea td i a g n o s i sw a s4 1
years(table 1). 22 of 25 patients are men, and 76% have
a history of smoking. Nine patients had a occupational
history of contact with dust, metal, silica, etc. the dura-
tion of occupational exposure ranged from 2 to 17
years. Most patients had comorbidity: pneumonia, tuber-
culosis, and fatty liver were the most common. 7 of 25
patients(28%) suffered from varying degrees of fatty liver
diagnosed by B Type Ultrasonography. On pulmonary
function testing, the most common pattern seen is that
of a restrictive defect, with a disproportionate reduction
Table 1 Baseline characteristics of patients
Characteristics N mean ± SD
Gender (M/F) 22/3




FEV1(L) 21 2.73 ± 0.5
FEV1/FVC(%) 21 88.89 ± 5.47
TLC (L) 21 4.03 ± 1.06
DLCO(mmol/min/kpa) 21 4.66 ± 1.82
Blood gas analysis
PaO2 (mmHg) 17 65 ± 14
PaCO2 (mmHg) 17 39 ± 3
PA-aO2 (mmHg) 17 36 ± 15
Serology
TC(mmol/L) 25 5.01 ± 1.08
TG(mmol/L) 25 1.7 ± 1.06
HDL-C(mmol/L) 25 1.11 ± 0.27
LDL-C(mmol/L) 25 3.07 ± 1.07
Apo-A1(mmol/L) 25 1.16 ± 0.38
Apo-B(mmol/L) 25 0.94 ± 0.28
Lipoprotein(a) (mg/L) 25 172 ± 63.6
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hypoxemia with 41% pressure of oxygen (PaO2) below
60 mmHg, While arterial carbon dioxide pressure
(PaCO2) was not significantly changed.
The serum lipid levels of patients with iPAP were
compared with those of the healthy volunteers(HA), as
shown in Figure 1. Except for HDL-C, patients with
iPAP had higher levels of TC, TG, LDL-C, LDL-C/
HDL-C, and lipoprotein(a) than did healthy controls.
However, there were no significant differences in TG
between the two groups(p > 0.05). In patients and
healthy subjects, the LDL-C/HDL-C ratios were 2.94 ±
1.21 and 1.60 ± 0.70, respectively (p <0 . 0 0 1 ) ,H D L - C
were 1.11 ± 0.27 and 1.71 ± 0.71 respectively (p <
0.001), LDL-C were 3.07 ± 1.07 and 2.43 ± 0.95 respec-
tively(p < 0.05), and Lipoprotein(a) were 172 ± 64 and
153 ± 85 respectively (p < 0.05).
Clinically, serum LDH level, PaO2, and alveolararterial
PA-aO2 have commonly been used to indicate the sever-
ity of iPAP[1,10]. The relations between these severity
markers and serum lipid levels were analyzed, and the
results are summarized in table 2. The values of LDL-C
correlated significantly with those of PaO2 and PA-aO2
(r = -0.685, p = 0.003, and r = 0.688, p =0 . 0 0 3 ,r e s p e c -
tively). A similar pattern was seen with LDL-C/HDL-C
ratios correlated negatively with PaO2 levels (r = -0.698,
p = 0.003) and positively with PA-aO2 (r = 0.653, p =
0.006). Apo-A1 was highly correlated with LDH and
PaO2, and lipoprotein(a) was highly correlated with
PaO2(table 2), whereas levels of TC, TG, HDL-C and
Apo-B did not show a correlation with any of the sever-
ity markers.
Serial changes in lipid levels and severity markers for
iPAP in two patients are shown in Figure 2. Two
patients had a different clinical course. In the patient
whose condition rapidly worsened (Figure 2A), the
aggravations in serum LDH, PA-aO2 and PaO2 were
associated with increase of LDL-C, LDL-C/HDL-C and
lipoprotein(a), although LDL-C and lipoprotein(a) were
somewhat unparalleled to severity markers at a time. In
the patient with three cycles of WLL(Figure 2B), the
changes of LDL-C, LDL-C/HDL-C and lipoprotein(a)
measured before each cycle of WLL were relatively par-
allel to severity markers.
Whole lung lavage was performed in 19 patients
(76%), of whom 2 patients underwent repeated lavage.
We analyzed oxygenation and serum lipid levels before
and after whole lung lavage(Figure 3). After lavage,
substantial improvement is often noted, particularly in
dyspnea. hypoxemia was corrected in eighty percent of
the patients for whom data were available. P(A-a)O2
and LDH were also improved after lung lavage(addi-
tional file 1). serum lipid levels before and after whole
lung lavage were available for 16 patients. Eleven
patients experienced a decline in TC levels following
whole lung lavage, the median decline was 0.71 mmol/
L(p < 0.009), A similar pattern was seen with LDL-C
in thirteen patients, the median decline was 0.47
mmol/L(p < 0.003). LDL-C/HDL-C, TG, HDL-C or
lipoprotein(a) showed a slight reduction after lavage,
Figure 1 Comparison of lipid levels between iPAP and HA.
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significant.
Discussion
A growing body of literature suggests that abnormal
lipid metabolism was associated with a variety of pul-
monary diseases, including chronic obstructive pulmon-
ary disease [11,12]and lung cancer[13,14]. Few previous
data describe the lipid profile associated with PAP. This
is the first study that has specifically evaluated the clini-
cal value of serum lipid levels in iPAP. We demon-
s t r a t e dt h a tt h el e v e l so fs e r u mL D L - Ca n dL D L - C /
HDL-C were significantly correlated with those of
serum PaO2 and P(A-a)O2. These findings indicate that
the serum lipid levels, especially the levels of LDL-C
and LDL-C/HDL-C, may reflect the severity of the dis-
ease in iPAP patients. Patients with iPAP exhibited ele-
vated lipid levels that were reduced significantly after
whole lung lavage. In addition, the present study sup-
ports the view that impaired lipid metabolism could be
present in iPAP[1,6]. These findings may expand the
role of serum lipid levels in iPAP.
Several studies have indicated that circulating lipopro-
tein levels would be changed in iPAP[1,5,6]. Elevated
cholesterol levels have been described in 19% of the
PAP patients, however, sample size and characteristics
were not available[1]. Tian et al.[6] reported that iPAP
associated with high triglyceride and low HDL-C levels
in the serum. Our results are in consistent with the
above findings, the high serum lipid levels did associate
with iPAP. Furthermore, twenty-eight percent of the
patients in this study suffered from varying degrees of
fatty liver which was resulted from hyperlipemia. It was
reported that the serum LDL-C/HDL-C ratios could
only reflect the severity of the disease[6]. In addition to
LDL-C/HDL-C ratios, LDL-C and lipoprotein(a) could
also serve as severity indicators in our present study.
Furthermore, whether the disease was improve or wor-
sen, the changes in serum LDL-C, LDL-C/HDL-C and
lipoprotein(a) were relatively parallel to those of the
severity markers in our study. However, this need large
cases to conformed.
The mechanisms responsible for dyslipoproteinemia in
iPAP are unknown, several observations could support a
link between iPAP pathophysiology and abnormal lipid
metabolism. The inflammatory cell most implicated in
both processes is the macrophage. Macrophages pro-
duce phospholipid transfer protein (PLTP) which is pre-
dominately found in the lungs[15]. PLTP are involved in
HDL-C metabolism and removing cholesterol from the
circulation[16]. Furthmore, PLTP can modulate choles-
terol deposition in macrophages through its role on oxi-
dative status inside the cells[17]. Alveolar macrophages
in PAP patients or murine models were found to exhibit
a reduced ability to degrade the surfactant, impaired cell
adhesion, ineffective phagocytosis and bacterial killing
[18,19]. These features were similar to those of the
immature macrophages which had obvious PLTP defi-
ciency[20]. PLTP may be one of the mechanisms
explaining dyslipoproteinemia in iPAP. It is unlikely,
however, that PLTP is the only factor involved in lipid
abnormalities in iPAP. Current thinking indicates that
iPAP is an autoimmune disorder characterized by circu-
lating anti-granulocyte macrophage colony stimulating
factor (GM-CSF) antibodies and dysfunction in GM-
CSF signaling[21]. GM-CSF, which has been verified to
involve in the pathophysiological procedure of PAP,
could also regulate serum protein and lipid catabolism
[22,23]. Further studies are required to clarify these
issues.
We further examined the effect of WLL on serum
lipid levels, findings demonstrated that the high lipid
levels observed prior to WLL would decline with WLL.
The effect of WLL in this study was somewhat counter-
intuitive. Local lavage can unexpectedly influence the
systemic lipid level. the reasonable explanation may be
that surfactant proteins produced locally in the lung
leak into the circulation. The alveolocapillary membrane,
a barrier, can be partitioning the proteins of the pul-
monary epithelial lining fluid, but there is some leakage









TC -0.264 0.213 -0.222 0.427 0.334 0.223
TG -0.152 0.468 0.297 0.264 -0.262 0.327
HDL-C -0.270 0.192 0.496 0.051 -0.452 0.079
LDL-C 0.153 0.465 -0.685 0.003 0.688 0.003
LDL-C/HDL-C 0.197 0.345 -0.698 0.003 0.653 0.006
apoA1 -0.535 0.006 0.514 0.042 -0.370 0.159
apoB 0.099 0.637 -0.041 0.880 0.056 0.837
Lipoprotein(a) 0.367 0.078 -0.546 0.016 0.441 0.058
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leak into the circulation. Moreover, accumulated data
have shown alveolocapillary membrane permeability was
markedly increased in PAP patients[24-26].
There are several limitations of this study. This is a
retrospective and single center study, represents a highly
selected group of subjects with very severe PAP, and
does not allow determination of mechanism. A
Figure 2 Serial data of lipid level and severity markers in two iPAP patients with a different clinical course:( A )ap a t i e n tw h o
progressivesly deteriorated and (B) a patient who required three cycles of therapeutic lung lavage. In (B), all the data were obtained before each
cycle of therapeutic lung lavage.
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significance of lipid metabolism in iPAP would be
required. However, the results could be of clinical rele-
vance since all studied subjects came from the same
institute, avoiding the inherent bias caused in multicen-
tre studies. In addition, the cases studied were limited
because iPAP is a rare disease. Further studies with lar-
ger samples of PAP patients are required.
Conclusions
In summary, we recommend that serum lipid levels
would provide valuable clinical information to assess
and monitor disease progression and predict the thera-
peutic effect of WLL. Furthermore, descending hyperli-
pemia may have potential value to clinical treatment of
iPAP.
Additional material
Additional file 1: Paired prelavage and postlavage severity markers
from patients with iPAP. PaO2, P(A-a)O2 and LDH were improved after
lung lavage.
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